The angiostatic protein 16K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells.

Virginie Kinet, Karolien Castermans, Stéphanie Herkenne, Catherine Maillard, Silvia Blacher, Michelle Lion, Agnès Noël, Joseph A Martial, Ingrid Struman

GIGA Research, Molecular Biology and Genetic Engineering Unit, University of Liège, 4000 Liège, Belgium.

Endocrinology 2011 Nov

filter terms:

The 16-kDa angiostatic N-terminal fragment of human prolactin (16K hPRL) has been reported to be a new potent anticancer compound. This protein has already proven its efficiency in several mouse tumor models in which it prevented tumor-induced angiogenesis and delayed tumor growth. In addition to angiogenesis, tumors also stimulate the formation of lymphatic vessels, which contribute to tumor cell dissemination and metastasis. However, the role of 16K hPRL in tumor-induced lymphangiogenesis has never been investigated. We establish in vitro that 16K hPRL induces apoptosis and inhibits proliferation, migration, and tube formation of human dermal lymphatic microvascular endothelial cells. In addition, in a B16F10 melanoma mouse model, we found a decreased number of lymphatic vessels in the primary tumor and in the sentinel lymph nodes after 16K hPRL treatment. This decrease is accompanied by a significant diminished expression of lymphangiogenic markers in primary tumors and sentinel lymph nodes as determined by quantitative RT-PCR. These results suggest, for the first time, that 16K hPRL is a lymphangiostatic as well as an angiostatic agent with antitumor properties.

Citation

Virginie Kinet, Karolien Castermans, Stéphanie Herkenne, Catherine Maillard, Silvia Blacher, Michelle Lion, Agnès Noël, Joseph A Martial, Ingrid Struman. The angiostatic protein 16K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells. Endocrinology. 2011 Nov;152(11):4062-71